Literature DB >> 12679808

Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme.

Sompop Bencharit1, Christopher L Morton, Yu Xue, Philip M Potter, Matthew R Redinbo.   

Abstract

We present the first crystal structures of a human protein bound to analogs of cocaine and heroin. Human carboxylesterase 1 (hCE1) is a broad-spectrum bioscavenger that catalyzes the hydrolysis of heroin and cocaine, and the detoxification of organophosphate chemical weapons, such as sarin, soman and tabun. Crystal structures of the hCE1 glycoprotein in complex with the cocaine analog homatropine and the heroin analog naloxone provide explicit details about narcotic metabolism in humans. The hCE1 active site contains both specific and promiscuous compartments, which enable the enzyme to act on structurally distinct chemicals. A selective surface ligand-binding site regulates the trimer-hexamer equilibrium of hCE1 and allows each hCE1 monomer to bind two narcotic molecules simultaneously. The bioscavenger properties of hCE1 can likely be used to treat both narcotic overdose and chemical weapon exposure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679808     DOI: 10.1038/nsb919

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  66 in total

1.  Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

Authors:  Jenna A Rhoades; Yuri K Peterson; Hao-Jie Zhu; David I Appel; Charles A Peloquin; John S Markowitz
Journal:  Pharm Res       Date:  2011-12-09       Impact factor: 4.200

2.  Mammalian carboxylesterase 3: comparative genomics and proteomics.

Authors:  Roger S Holmes; Laura A Cox; John L VandeBerg
Journal:  Genetica       Date:  2010-04-28       Impact factor: 1.082

3.  Simulation on the structure of pig liver esterase.

Authors:  Daniel Hasenpusch; Uwe T Bornscheuer; Walter Langel
Journal:  J Mol Model       Date:  2010-09-24       Impact factor: 1.810

4.  Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

Authors:  M J Hatfield; L Tsurkan; J L Hyatt; X Yu; C C Edwards; L D Hicks; R M Wadkins; P M Potter
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2.

Authors:  Yun-Qing Song; Rong-Jing He; Dan Pu; Xiao-Qing Guan; Jin-Hui Shi; Yao-Guang Li; Jie Hou; Shou-Ning Jia; Wei-Wei Qin; Sheng-Quan Fang; Guang-Bo Ge
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

6.  Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid.

Authors:  Mohit P Mathew; Elaine Tan; Jason W Labonte; Shivam Shah; Christopher T Saeui; Lingshu Liu; Rahul Bhattacharya; Patawut Bovonratwet; Jeffrey J Gray; Kevin J Yarema
Journal:  Chembiochem       Date:  2017-04-20       Impact factor: 3.164

7.  Evaluation of a pharmacokinetic hypothesis for reduced locomotor stimulation from methamphetamine and cocaine in adolescent versus adult male C57BL/6J mice.

Authors:  Jonathan A Zombeck; Tripta Gupta; Justin S Rhodes
Journal:  Psychopharmacology (Berl)       Date:  2008-09-17       Impact factor: 4.530

Review 8.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

9.  Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen").

Authors:  M Jason Hatfield; Randall J Binder; Rowan Gannon; Ellie M Fratt; John Bowling; Philip M Potter
Journal:  J Nat Prod       Date:  2018-10-23       Impact factor: 4.050

10.  Baboon carboxylesterases 1 and 2: sequences, structures and phylogenetic relationships with human and other primate carboxylesterases.

Authors:  Roger S Holmes; Jeremy P Glenn; John L VandeBerg; Laura A Cox
Journal:  J Med Primatol       Date:  2009-02       Impact factor: 0.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.